ClinicalTrials.gg
CompletedNCT04526119Updated Jul 24, 2026

A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia

A Phase 3 interventional study of Acotiamide hydrochloride hydrate and Placebo in Functional Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 1 site in Japan. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Zeria Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Enrollment
9th of 11
55 · median 282
Started
2021
the only one that year
Phase 3
4 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
7 of 11
Zeria Pharmaceutical

Among the 11 studies testing Z 338 in Dyspepsia, this one is the 9th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 3, and was the 10th registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 9 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate pharmacokinetics, efficacy and safety of Z-338 of pediatric patients with functional dyspepsia (FD).

In Part 1, the pharmacokinetics and safety of single oral dose of Z-338 100 mg are evaluated.

In Part 2, the efficacy and safety of Z-338 100 mg orally 3 times daily before meals are evaluated.

Part 2 is comprised by the double-blind phase and the open-label phase. In the double-blind phase, subjects will take Z-338 or placebo for 28 days. In the open-label phase, all subjects will take Z-338 for 28 days.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

Part 1\& Part 2

  • Subjects aged from nine to 17 years (from nine to 14 years in Part 1), on the day the is signed.
  • Subjects with a diagnosis of FD as defined by the Rome IV Criteria.
  • Subjects who have postprandial fullness, upper abdominal bloating or early satiation.

Part 2 only

  • Subjects who have postprandial fullness, upper abdominal bloating or early satiation during with a certain severity during a week prior to the day of randomization.

Main Exclusion Criteria:

Part 1\&Part 2

  • Subject who have organic diseases of the gastrointestinal tract or gastrointestinal bleeding within 24 weeks prior to informed consent.
  • Subject who have received Helicobacter pylori eradication therapy within 24 weeks prior to informed consent, or subjects who is defined as Helicobacter pylori-positive within 4 weeks prior to or on the day the informed consent is signed.
  • Subjects who have alarm symptom on the day the informed consent is signed.
  • Subjects who have food allergy of unknown origin or uncontrolled food allergy.

Part 2 only

  • Subject taking drugs used for FD within 2 weeks prior to the day of randomization (excluding proton pump inhibitors)
  • Subject taking proton pump inhibitors within 4 weeks prior to the day of randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Z-338

    Drug: Acotiamide hydrochloride hydrate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase

  • DrugPlacebo

    A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase

06

What researchers measure

Primary outcomes

  1. Cmax of single dose Z-338 before meal

    Time frame: The 1 day of single dose

  2. AUC up to 8 hours after administration of single dose Z-338 before meal

    Time frame: The 1 day of single dose

  3. Elimination rate of three symptoms (Postprandial fullness, Upper abdominal bloating and Early satiation)

    Time frame: At week 4 of treatment or treatment discontinuation

  4. Overall responder rate by the Overall Treatment Evaluation (OTE) scale

    Time frame: At week 4 of treatment or treatment discontinuation

Secondary outcomes

  1. Elimination rate of each symptom

    Time frame: Weekly from the day of randomization to Week 8

  2. Average severity score of each symptom

    Time frame: Weekly from the day of randomization to Week 8

  3. Worst severity score of each symptom

    Time frame: Weekly from the day of randomization to Week 8

  4. Weekly responder rate by the OTE scale

    Time frame: Weekly from the day of randomization to Week 8

  5. Incidence of adverse events

    Time frame: 8-weeks study period

  6. Incidence of adverse drug reactions

    Time frame: 8-weeks study period

07

Study locations

1 site
  • Zeria Investigative Site
    Matsumoto, Nagano, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2026, 60 months.

Of 15 phase 3 interventional studies under Dyspepsia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 25, 2020
StartActual
Feb 22, 2021
Primary completionActual
Mar 2, 2026
CompletionActual
May 8, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04526119
Responsible party
Sponsor
First posted
Aug 25, 2020
Start date
Feb 22, 2021
Primary completion
Mar 2, 2026
Completion
May 8, 2026
Last update
Jul 24, 2026

Study contacts

Yuji Shibasaki
study director · Zeria Pharmaceutical

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion